Zhenyu Xu Sells 10,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $8.91, for a total transaction of $89,100.00. Following the completion of the sale, the insider owned 556,887 shares of the company’s stock, valued at $4,961,863.17. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total transaction of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.

SOPHiA GENETICS Stock Up 0.4%

Shares of SOPH stock opened at $8.43 on Wednesday. The stock’s 50 day simple moving average is $6.64 and its 200 day simple moving average is $5.51. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market capitalization of $707.19 million, a price-to-earnings ratio of -7.33 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. As a group, research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SOPH shares. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research raised their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the period. AWM Investment Company Inc. bought a new stake in SOPHiA GENETICS in the 2nd quarter valued at $9,809,000. Akre Capital Management LLC increased its holdings in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares during the period. Hodges Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $2,157,000. Finally, Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $2,009,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.